Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian G Feagan

Showing results (341-350 of 464) with videos related to

Pageof 47
Sort By:
The American Journal of Gastroenterology|September 16, 2022
Rapid and Sustained Symptom Relief in Patients With Ulcerative Colitis Treated With Filgotinib: Data From the Phase 2b/3 SELECTION TrialSilvio Danese, Marc Ferrante, Brian G Feagan, et al.
Gastroenterology|July 5, 2011
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitisJean Frédéric Colombel, Paul Rutgeerts, Walter Reinisch, et al.
The New England Journal of Medicine|August 23, 2013
Vedolizumab as induction and maintenance therapy for ulcerative colitisBrian G Feagan, Paul Rutgeerts, Bruce E Sands, et al.
Gastroenterology|July 15, 2009
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximabWilliam J Sandborn, Paul Rutgeerts, Brian G Feagan, et al.
The New England Journal of Medicine|August 23, 2013
Vedolizumab as induction and maintenance therapy for Crohn's diseaseWilliam J Sandborn, Brian G Feagan, Paul Rutgeerts, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 2, 2019
Reliability of Endoscopic Evaluation of Postoperative Recurrent Crohn's DiseaseChristopher Ma, Krisztina B Gecse, Marjolijn Duijvestein, et al.
The American Journal of Gastroenterology|May 9, 2020
Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule InhibitorsParambir S Dulai, Robert Battat, Maria Barsky, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 6, 2025
A Phase 2 Study of MORF-057, an Oral α4β7 Integrin Inhibitor in Moderately to Severely Active Ulcerative ColitisBruce E Sands, Stefan Schreiber, Silvio Danese, et al.
The New England Journal of Medicine|September 29, 2021
Ozanimod as Induction and Maintenance Therapy for Ulcerative ColitisWilliam J Sandborn, Brian G Feagan, Geert D'Haens, et al.
Journal of Crohn'S & Colitis|November 9, 2025
Placebo rates in randomized clinical trials of ulcerative colitis: an individual patient data meta-analysisVirginia Solitano, Malcolm Hogan, Siddharth Singh, et al.
Pageof 47

Showing results (341-350 of 464) with videos related to

Sort By:
Pageof 47
The American Journal of Gastroenterology|September 16, 2022
Rapid and Sustained Symptom Relief in Patients With Ulcerative Colitis Treated With Filgotinib: Data From the Phase 2b/3 SELECTION TrialSilvio Danese, Marc Ferrante, Brian G Feagan, et al.
Gastroenterology|July 5, 2011
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitisJean Frédéric Colombel, Paul Rutgeerts, Walter Reinisch, et al.
The New England Journal of Medicine|August 23, 2013
Vedolizumab as induction and maintenance therapy for ulcerative colitisBrian G Feagan, Paul Rutgeerts, Bruce E Sands, et al.
Gastroenterology|July 15, 2009
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximabWilliam J Sandborn, Paul Rutgeerts, Brian G Feagan, et al.
The New England Journal of Medicine|August 23, 2013
Vedolizumab as induction and maintenance therapy for Crohn's diseaseWilliam J Sandborn, Brian G Feagan, Paul Rutgeerts, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 2, 2019
Reliability of Endoscopic Evaluation of Postoperative Recurrent Crohn's DiseaseChristopher Ma, Krisztina B Gecse, Marjolijn Duijvestein, et al.
The American Journal of Gastroenterology|May 9, 2020
Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule InhibitorsParambir S Dulai, Robert Battat, Maria Barsky, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 6, 2025
A Phase 2 Study of MORF-057, an Oral α4β7 Integrin Inhibitor in Moderately to Severely Active Ulcerative ColitisBruce E Sands, Stefan Schreiber, Silvio Danese, et al.
The New England Journal of Medicine|September 29, 2021
Ozanimod as Induction and Maintenance Therapy for Ulcerative ColitisWilliam J Sandborn, Brian G Feagan, Geert D'Haens, et al.
Journal of Crohn'S & Colitis|November 9, 2025
Placebo rates in randomized clinical trials of ulcerative colitis: an individual patient data meta-analysisVirginia Solitano, Malcolm Hogan, Siddharth Singh, et al.
Pageof 47